Rigel Pharmaceuticals, Inc. (RIGL) wird mit einem nachlaufenden KGV von gehandelt 1.5, erwartetes KGV von 7.4. Die nachlaufende Gewinnrendite beträgt 68.13%, erwartete Gewinnrendite 13.55%. Die Graham-Zahl beträgt $99.96.
Durch diese Seite bewiesene Kriterien:
SharesGrow Gesamtbewertung: 78/100 mit 4/7 Kriterien bestanden.
| Year | P/E (TTM) | PEG-Verhältnis | P/B-Verhältnis | P/S-Verhältnis | Dividendenrendite |
|---|---|---|---|---|---|
| 2016 | -3.2 | -0.13 | 4.08 | 11.02 | - |
| 2017 | -6.3 | 0.40 | 4.87 | 109.30 | - |
| 2018 | -5.2 | 0.18 | 3.36 | 8.30 | - |
| 2019 | -5.4 | 0.59 | 6.65 | 6.04 | - |
| 2020 | -19.9 | 0.36 | 17.36 | 5.44 | - |
| 2021 | -25.2 | 0.65 | 14.87 | 3.03 | - |
| 2022 | -4.4 | -0.02 | -18.99 | 2.15 | - |
| 2023 | -10.1 | 0.17 | -8.81 | 2.16 | - |
| 2024 | 16.9 | -0.10 | 89.93 | 1.65 | - |
| 2025 | 2.1 | 0.00 | 1.97 | 2.62 | - |
| Year | EPS (verwässert) | Umsatz | Nettogewinn | Nettomarge |
|---|---|---|---|---|
| 2016 | $-7.33 | $20.38M | $-69.22M | -339.6% |
| 2017 | $-6.17 | $4.48M | $-77.99M | -1739.3% |
| 2018 | $-4.40 | $44.51M | $-70.48M | -158.3% |
| 2019 | $-4.00 | $59.29M | $-66.55M | -112.2% |
| 2020 | $-1.80 | $108.62M | $-29.74M | -27.4% |
| 2021 | $-1.05 | $149.24M | $-17.91M | -12% |
| 2022 | $-3.40 | $120.24M | $-58.57M | -48.7% |
| 2023 | $-1.44 | $116.88M | $-25.09M | -21.5% |
| 2024 | $0.99 | $179.28M | $17.49M | 9.8% |
| 2025 | $19.48 | $294.28M | $367.02M | 124.7% |
| Year | EPS (Durchschn.) | EPS-Spanne | Umsatz (Durchschn.) | Umsatzspanne | Analysten |
|---|---|---|---|---|---|
| 2026 | $4.35 | $3.70 – $4.84 | $284.13M | $282.02M – $286.22M | 3 |
| 2027 | $4.17 | $4.03 – $4.30 | $320.34M | $298.41M – $342.27M | 3 |
| 2028 | $4.44 | $3.22 – $5.84 | $355.59M | $355.59M – $355.59M | 4 |
| 2029 | $3.22 | $3.08 – $3.44 | $358.83M | $346.5M – $377.03M | 2 |
| 2030 | $3.79 | $3.62 – $4.04 | $387.83M | $374.51M – $407.5M | 2 |
